UA101057C2 - Pyrimidine derivatives as kinase inhibitors - Google Patents

Pyrimidine derivatives as kinase inhibitors

Info

Publication number
UA101057C2
UA101057C2 UAA201104068A UAA201104068A UA101057C2 UA 101057 C2 UA101057 C2 UA 101057C2 UA A201104068 A UAA201104068 A UA A201104068A UA A201104068 A UAA201104068 A UA A201104068A UA 101057 C2 UA101057 C2 UA 101057C2
Authority
UA
Ukraine
Prior art keywords
pyrimidine derivatives
kinase inhibitors
analplastic
igf
alk
Prior art date
Application number
UAA201104068A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
ИИИ Томас Х. Марсилье
Уэншуо Лу
Бей Чен
Ксяогуй Хи
Кристиан Чо-Хуа Ли
Сонгчун Джианг
Кунйонг Янг
Original Assignee
Айерем Элелси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айерем Элелси filed Critical Айерем Элелси
Priority claimed from PCT/US2009/048428 external-priority patent/WO2010002655A2/en
Publication of UA101057C2 publication Critical patent/UA101057C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin- like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
UAA201104068A 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors UA101057C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
PCT/US2009/048428 WO2010002655A2 (en) 2008-06-25 2009-06-24 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
UA101057C2 true UA101057C2 (en) 2013-02-25

Family

ID=41076758

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201104068A UA101057C2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors

Country Status (11)

Country Link
EP (1) EP2331526A2 (en)
JP (1) JP2011526291A (en)
KR (1) KR20110020940A (en)
CN (1) CN102203083A (en)
AU (1) AU2009262198B2 (en)
BR (1) BRPI0914545A2 (en)
CA (1) CA2729546A1 (en)
EA (1) EA201100078A1 (en)
MX (1) MX2010014568A (en)
UA (1) UA101057C2 (en)
WO (1) WO2009158431A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
BR112014011219B1 (en) * 2011-11-29 2022-08-23 Genentech, Inc. AMINOPYRIMIDINE DERIVATIVES, THEIR USES, AND PHARMACEUTICAL COMPOSITION
ES2728008T3 (en) 2012-11-06 2019-10-21 Shanghai Fochon Pharmaceutical Co Ltd ALK kinase inhibitors
HUE044558T2 (en) * 2013-03-14 2019-11-28 Tolero Pharmaceuticals Inc Jak2 and alk2 inhibitors and methods for their use
WO2015180685A1 (en) * 2014-05-30 2015-12-03 北京浦润奥生物科技有限责任公司 Alk kinase inhibitor, and preparation method and use thereof
CN110312711A (en) * 2016-10-07 2019-10-08 亚瑞克西斯制药公司 Heterocyclic compound and its application method as RAS inhibitor
CN107488148A (en) * 2017-06-26 2017-12-19 安徽省黄淮兽药有限公司 A kind of hydrocinnamamide insecticides and preparation method thereof
IL275490B2 (en) 2017-12-22 2024-05-01 Ravenna Pharmaceuticals Inc Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202045008A (en) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-substituted isoxazole/isoxazoline (hetero) arylamidine compounds, preparation and use thereof
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
AU2021218739A1 (en) * 2020-02-14 2022-09-22 Salk Institute For Biological Studies Inhibitors of ULK1/2 and methods of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
ES2421139T3 (en) * 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP1663242B1 (en) * 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP2007505858A (en) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 2,4-Di (phenylamino) pyrimidine useful for the treatment of proliferative disorders
US8211929B2 (en) * 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
GEP20156282B (en) * 2006-12-08 2015-05-11 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0720264B1 (en) * 2006-12-08 2022-03-03 Novartis Ag COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
MX2010008700A (en) * 2008-02-22 2010-08-30 Hoffmann La Roche Modulators for amyloid beta.

Also Published As

Publication number Publication date
EP2331526A2 (en) 2011-06-15
AU2009262198A1 (en) 2009-12-30
AU2009262198B2 (en) 2012-09-27
CN102203083A (en) 2011-09-28
CA2729546A1 (en) 2009-12-30
MX2010014568A (en) 2011-03-29
WO2009158431A2 (en) 2009-12-30
BRPI0914545A2 (en) 2017-05-23
KR20110020940A (en) 2011-03-03
WO2009158431A3 (en) 2010-03-11
JP2011526291A (en) 2011-10-06
EA201100078A1 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
WO2010002655A3 (en) Pyrimidine derivatives as kinase inhibitors
UA101057C2 (en) Pyrimidine derivatives as kinase inhibitors
MX2010002336A (en) Compounds and compositions as kinase inhibitors.
UA100846C2 (en) Compounds and compositions as protein kinase inhibitors
TN2009000225A1 (en) Compounds and compositions as protein kinase kinase inhibitors
MX2010010968A (en) Compounds and compositions as protein kinase inhibitors.
WO2009126514A8 (en) Compounds and compositions as kinase inhibitors
MX2012000711A (en) Pyrrolopyrazine inhibitors of kinases.
MX2012013197A (en) Indazole inhibitors of kinase.
MX2009000884A (en) Pyridizinone derivatives.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2011013325A (en) 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors.
MX2012000709A (en) Pyrrolopyridine inhibitors of kinases.
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MX336726B (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors.
MX2011012629A (en) Pyrimidine inhibitors of kinase activity.
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
MX2009004140A (en) Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors.
MX2011012631A (en) Pyrimidine inhibitors of kinase activity.
MX2011012632A (en) Pyrimidine inhibitors of kinase activity.
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2010039668A3 (en) Inhibitors of cyclin kinase inhibitor p21
MX2010004604A (en) Pyrazole derivatives as 5-lo inhibitors.
MX2009012079A (en) Condensed heterocyclic compounds as inhibitors of protein kinases.
MX2009003793A (en) Kinase inhibitors.